Volume 32, Issue 2 (Avicenna Journal of Clinical Medicine-Summer 2025)
Avicenna J Clin Med 2025, 32(2): 118-126 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Vahidnia S, Kasani A, Eatedali H, Ghasemi E. Evaluation of the Treatment Process for Cutaneous Leishmaniasis Patients Referred to the Reference Center for Diagnosis and Treatment of Leishmaniasis in Dezful, Iran. Avicenna J Clin Med 2025; 32 (2) :118-126
URL: http://sjh.umsha.ac.ir/article-1-3248-en.html
URL: http://sjh.umsha.ac.ir/article-1-3248-en.html
1- Student Research Committees, Dezful University of Medical Sciences, Dezful, Iran
2- Department of Community Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
3- Department of Medical Parasitology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran & Infectious and Tropical Diseases Research Center, Dezful University of Medical Sciences, Dezful, Iran ,ezatqassemi@gmail.com
2- Department of Community Medicine, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran
3- Department of Medical Parasitology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran & Infectious and Tropical Diseases Research Center, Dezful University of Medical Sciences, Dezful, Iran ,
Abstract: (88 Views)
Background and Objective: The clinical manifestations of cutaneous leishmaniasis exhibit significant heterogeneity, ranging from self-limiting lesions to atypical presentations. Relapses, treatment failures, and drug resistance in cutaneous leishmaniasis treatment pose substantial challenges. For this reason, the present study aimed to assess the treatment process of patients with cutaneous leishmaniasis referred to the Diagnosis and Treatment Reference Center of Dezful University of Medical Sciences.
Materials and Methods: This cross-sectional descriptive study, conducted from April 2021 to March 2023, involved 296 patients with cutaneous leishmaniasis at Dezful University of Medical Sciences. Three Giemsa-stained smears were prepared for each patient, and their treatment was meticulously monitored, strictly adhering to national guidelines. The study sought to evaluate the diagnosis and treatment outcomes of cutaneous leishmaniasis within the patient cohort, employing descriptive statistics and chi-square testing, with a significance threshold of P≤ 0.05.
Results: The present study on cutaneous leishmaniasis treatment outcomes provides valuable insights. Of the 296 patients under treatment, 105 (35.7%) cases were female, and 191 (64.3%) subjects were male. The mean age scores of males and females were reported as 27.16±17.77 and 25.45±20.39 years, respectively. The most common lesion site was the hands, with 121 (40.9%) patients having lesions on their hands. Notably, of the 296 cases treated according to the national standard protocol, only a tiny percentage experienced relapse (1.68%), treatment failure (1.01%), or drug resistance (0.33%), while the vast majority (96.5%) achieved a complete cure. These findings underscore the need for further research to improve our understanding of cutaneous leishmaniasis treatment.
Conclusion: As evidenced by the results of this study, despite strict adherence to national guidelines, treatment failures, relapses, and drug resistance remain daunting challenges presented to cutaneous leishmaniasis patients treated with pentavalent antimonials
Materials and Methods: This cross-sectional descriptive study, conducted from April 2021 to March 2023, involved 296 patients with cutaneous leishmaniasis at Dezful University of Medical Sciences. Three Giemsa-stained smears were prepared for each patient, and their treatment was meticulously monitored, strictly adhering to national guidelines. The study sought to evaluate the diagnosis and treatment outcomes of cutaneous leishmaniasis within the patient cohort, employing descriptive statistics and chi-square testing, with a significance threshold of P≤ 0.05.
Results: The present study on cutaneous leishmaniasis treatment outcomes provides valuable insights. Of the 296 patients under treatment, 105 (35.7%) cases were female, and 191 (64.3%) subjects were male. The mean age scores of males and females were reported as 27.16±17.77 and 25.45±20.39 years, respectively. The most common lesion site was the hands, with 121 (40.9%) patients having lesions on their hands. Notably, of the 296 cases treated according to the national standard protocol, only a tiny percentage experienced relapse (1.68%), treatment failure (1.01%), or drug resistance (0.33%), while the vast majority (96.5%) achieved a complete cure. These findings underscore the need for further research to improve our understanding of cutaneous leishmaniasis treatment.
Conclusion: As evidenced by the results of this study, despite strict adherence to national guidelines, treatment failures, relapses, and drug resistance remain daunting challenges presented to cutaneous leishmaniasis patients treated with pentavalent antimonials
Type of Study: Original |
Subject:
Parasitology & Mycology
References
1. Akilov OE, Khachemoune A, Hasan T. Clinical manifestations and classification of old world cutaneous leishmaniasis. Int J Dermatol. 2007;46(2):132-42. PMID: 17269962 DOI: 10.1111/j.1365-4632.2007.03154.x
2. Mohebali M, Nadim A, Khamesipour A. An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines. Acta Trop. 2019;200:105173. PMID: 31525323 DOI: 10.1016/j.actatropica.2019.105173
3. Nasiri Z, Kalantari M, Mohammadi J, Daliri S, Mehrabani D, Azizi K. Cutaneous leishmaniasis in Iran: A review of epidemiological aspects, with emphasis on molecular findings. Parasite. 2022;29:47. PMID: 36269100 DOI: 10.1051/parasite/2022047
4. Jalali H, Enayati AA, Fakhar M, Motevalli-Haghi F, Yazdani Charati J, Dehghan O, et al. Reemergence of zoonotic cutaneous leishmaniasis in an endemic focus, northeastern Iran. Parasite Epidemiol Control. 2021;13:e00206. PMID: 33889761 DOI: 10.1016/j.parepi.2021.e00206
5. Feiz Haddad MH, Ghasemi E, Maraghi S, Tavala M. Identification of leishmania species isolated from human cutaneous leishmaniasis in Mehran, western Iran using nested PCR. Iran J Parasitol. 2016;11(1):65-72. PMID: 27095970
6. . Bassaid A, Merad Y, Ait Si Ali MO, Djeridane A, Bachi F, Adjmi-Hamoudi H. Cutaneous sporotrichoid leishmaniasis: An atypical case caused by leishmania major. IDCases. 2022;30:e01629. PMID: 36353702 DOI: 10.1016/j.idcr.2022.e01629
7. Ghasemi E, Ghaffarifar F, Dalimi A, Sadraei J. In-vitro and in-vivo antileishmanial activity of a compound derived of platinum, oxaliplatin, against Leishmania major. Iran J Pharm Res. 2019;18(4):2028-41. PMID: 32184867 DOI: 10.22037/ijpr.2019.15364.13046
8. Alizadeh Z, Shirzadi MR, Hassanpour GR, Keshavarz H, Mohebali F, Eskandari SE, et al. Field efficacy of topical nano-liposomal amphotericin b (sina ampholeish®) alone or in combination with glucantime® and cryotherapy on human cutaneous leishmaniasis. Iran J Parasitol. 2023;18(4):419-426. PMID: 38169758 DOI: 10.18502/ijpa.v18i4.14241
9. Santos GA, Sousa JM, Aguiar AHBM, Torres KCS, Coelho AJS, Ferreira AL, et al. Systematic review of treatment failure and clinical relapses in leishmaniasis from a multifactorial perspective: clinical aspects, factors associated with the parasite and host. Trop Med Infect Dis. 2023;8(9):430. PMID: 37755891 DOI: 10.3390/tropicalmed8090430
10. Zhang H, Yan R, Liu Y, Yu M, He Z, Xiao J, et al. Progress in antileishmanial drugs: Mechanisms, challenges, and prospects. PLoS Negl Trop Dis. 2025;19(1):e0012735. PMID: 39752369 DOI: 10.1371/journal.pntd.0012735
11. Razavi MR, Shirzadi MR, Mohebali M, Yaghoobi-Ershadi MR, Vatandoost H, Shirzadi M, et al. Human cutaneous leishmaniosis in Iran, up to date-2019. J Arthropod Borne Dis. 2021;15(2):143-151. PMID: 35111852 DOI: 10.18502/jad.v15i2.7483
12. Fatholahizadeh A, Mashayekhi A, Nayeri T, Ghasemi E. Molecular identification and characterization of the causative species of cutaneous leishmaniasis in Dezful city, southwest Iran. Open Microbiol J. 2025;19.DOI: 10.2174/0118742858367382250131080915
13. World Health Organization. Basic laboratory methods in medical parasitology. WHO; 1991. Link
14. Magill AJ. Cutaneous leishmaniasis in the returning traveler. Infect Dis Clin North Am. 2005;19(1):241-66. PMID: 15701556 DOI: 10.1016/j.idc.2004.11.005
15. Walker J, Gongora R, Vasquez JJ, Drummelsmith J, Burchmore R, Roy G, et al. Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. Mol Biochem Parasitol. 2012;183(2):166-76. PMID: 22449941 DOI: 10.1016/j.molbiopara.2012.03.002
16. Hamarsheh O, Nasereddin A, Damaj S, Sawalha S, Al-Jawabreh H, Azmi K, et al. Serological and molecular survey of Leishmania parasites in apparently healthy dogs in the West Bank, Palestine. Parasit Vectors. 2012;5:183. PMID: 22937916 DOI: 10.1186/1756-3305-5-183
17. Kolaczinski J, Brooker S, Reyburn H, Rowland M. Epidemiology of anthroponotic cutaneous leishmaniasis in Afghan refugee camps in northwest Pakistan. Trans R Soc Trop Med Hyg. 2004;98(6):373-8. PMID: 15099994 DOI: 10.1016/j.trstmh.2003.11.003
18. Saki J, Khademvatan S. A molecular study on cutaneous leishmaniasis lesions in Khuzestan province (South west of Iran). Jundishapur J Microbiol. 2011;4(4):283-8. Link
19. Farahmand M, Nahrevanian H, Shirazi HA, Naeimi S, Farzanehnejad Z. An overview of a diagnostic and epidemiologic reappraisal of cutaneous leishmaniasis in Iran. Braz J Infect Dis. 2011;15(1):17-21. PMID: 21412584
20. Bamorovat M, Sharifi I, Dabiri S, Shamsi Meymandi S, Karamoozian A, Amiri R, et al. Major risk factors and histopathological profile of treatment failure, relapse and chronic patients with anthroponotic cutaneous leishmaniasis: A prospective case-control study on treatment outcome and their medical importance. PLoS Negl Trop Dis. 2021;15(1):e0009089. PMID: 33507940 DOI: 10.1371/journal.pntd.0009089
21. Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052. PMID: 29240765 DOI: 10.1371/journal.pntd.0006052
22. Cozzani E, Satta R, Fausti V, Cottoni F, Parodi A. Cutaneous sporotrichoid leishmaniasis resistant to pentavalent antimonial therapy: complete resolution with itraconazole. Clin Exp Dermatol. 2011;36(1):49-51. PMID: 20545956 DOI: 10.1111/j.1365-2230.2010.03855.x
23. Remadi L, Haouas N, Chaara D, Slama D, Chargui N, Dabghi R, et al. Clinical presentation of cutaneous leishmaniasis caused by Leishmania major. Dermatology. 2016;232(6):752-9. PMID: 28253508 DOI: 10.1159/000456543
24. Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther. 2014;12(8):937-46. PMID: 24802998 DOI: 10.1586/14787210.2014.916614
25. Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int. 2011;2011:571242. PMID: 22091408 DOI: 10.4061/2011/571242
26. Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis. 2012;6(6):e1674. PMID: 22724029 DOI: 10.1371/journal.pntd.0001674
27. Berg M, Mannaert A, Vanaerschot M, Van Der Auwera G, Dujardin JC. (Post-) Genomic approaches to tackle drug resistance in Leishmania. Parasitology. 2013;140(12):1492-505. PMID: 23480865 DOI: 10.1017/S0031182013000140
28. Mannaert A, Downing T, Imamura H, Dujardin JC. Adaptive mechanisms in pathogens: universal aneuploidy in leishmania. Trends Parasitol. 2012;28(9):370-6. PMID: 22789456 DOI: 10.1016/j.pt.2012.06.003
29. Holakouie-Naieni K, Mostafavi E, Boloorani AD, Mohebali M, Pakzad R. Spatial modeling of cutaneous leishmaniasis in Iran from 1983 to 2013. Acta Trop. 2017;166:67-73. PMID: 27836499 DOI: 10.1016/j.actatropica.2016.11.004
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Articles Copyright © The Author(s).
Owned by Hamadan University of Medical Sciences
Published by UMSHA Press
Journal Tel: +988138380924
Publisher Tel:+988138380548
Website: http://sjh.umsha.ac.ir
Email: s_ journal[at]umsha.ac.ir
